What Do GSK (LSE:GSK) ESMO Cancer Trial Updates Mean For Its Oncology Pipeline?

• GSK (LSE:GSK) presented new late-breaking clinical trial results for its ADCs mocertatug rezetecan and risvutatug rezetecan at ESMO Congress 2026.
• Updated data for Mo-Rez covered pivotal phase III programmes in ovarian, endometrial and small cell lung cancers, including objective response rate and progression-free survival metrics.
• Ris-Rez data outlined multi-indication plans in solid tumours, signalling broader ambitions for GSK's oncology pipeline beyond recently discussed FDA approvals.
• These fresh ESMO 2026 results for Mo-Rez and Ris-Rez deserve to be weighed against the rest of GSK's investment picture. We have also spotted 3 warning signs worth knowing about at GSK.

For readers tracking how cancer drug development and AI-enabled discovery are reshaping healthcare, this wider opportunity set is worth exploring through 9 healthcare AI stocks.

GSK is a £74.4b pharmaceuticals group focused on vaccines, specialty treatments and general medicines across the UK, US and other markets. These oncology antibody drug conjugate studies sit within a broader effort to develop targeted therapies for complex diseases.

3 things going right for GSK that this headline doesn't cover.

How fresh Mo Rez and Ris Rez data stress test the GSK Narrative

For GSK, the investment story rests on oncology and other specialty medicines picking up more of the load as older therapies come under pressure, with late stage assets turning into real products rather than just pipeline headlines. These ESMO 2026 readouts for Mo Rez and Ris Rez directly probe whether that Narrative is grounded in evidence or still mostly promise.

"The main thing that has to go right is that GSK converts its enlarged late stage pipeline, particularly in oncology and long acting HIV and liver disease programs, into commercially meaningful products..."

See how the full story points towards a £21.73 fair value for GSK.

The Mo Rez and Ris Rez updates clearly support the part of the GSK thesis that focuses on antibody drug conjugates as a potential specialty medicines engine. Objective response rates, progression free survival and dose selection data move both assets closer to the kind of late stage clarity that investors consider when comparing GSK with peers such as AstraZeneca and Roche.

The same news also raises the bar on a second Narrative pillar, which is the Accelerate Growth cost savings program funding more than 20 Phase III starts without squeezing margins. Expanding multi indication Phase III plans for these ADCs increases R&D and commercial execution demands, so the existing minor risks around high debt and one off items matter more if trial outcomes or launches encounter setbacks.

Ultimately, updates like these only make sense in the context of where GSK is trying to go, which is exactly what a clear Narrative forces you to weigh before reacting to any single data release.

Add GSK to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com